Industry news

• Industry news
• Immunology and Allergy

Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety

Mainz, Germany, August 04, 2010 - A clinical first-in-human Phase I multi center study with GANYMED's monoclonal antibody iMAB362 demonstrated excellent safety up to a dosis of 1g/sqm in gastro-esophageal cancer patients. iMAB362 targets GANYMED's proprietary cell surface antigen Claudine 18.2, which is present in 70% of all gastric cancers, 50% pancreatic cancers, 30% esophageal cancers and 25% non small cell lung (NSCL) cancers. In preclinical cancer models iMAB362 demonstrated potent... more

Two-Thirds Respond to "Re-vaccination "

August 01, 2010 -- Study Highlights: 25 volunteers from previously conducted Phase 2a trial were "re-vaccinated" with the vaccine after 7 years as part of a Phase 2 trial. Two thirds of the study volunteers responded to re-vaccination with Vacc-4x, resulting in enhanced immune response to their HIV-virus. Vacc-4x was also found to trigger 'killer T-cells' that function to seek out and kill HIV-infected cells in the body, which is in line with the objective of a successful T-cell vaccine.... more

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
Category	Therapeutic target
Deals and Alliances Development Financial Results Financings Intellectual Property Regulatory	Cardiovascular Dermatology Endocrine and Metabolic Gastroenterology Genitourinary Hematology Immunology and Allergy Infection Musculoskeletal Neurology Obstetrics and Gynecology Oncology Ophthalmology Psychiatry Pulmonary
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Most Viewed

Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety

Two-Thirds Respond to "Re-vaccination "